Table 2 Multivariable regression analysis of risk factors for residual neuromuscular block using administration of Sugammadex following primary reversal with neostigmine as a surrogate outcome

Age (10-year increments)

1.22

(1.17 to 1.26)

< 0.001

Body mass index (kg/m²) (units of 5)

1.21

(1.16 to 1.24)

< 0.001

ASA 1 or 2*

-

-

-

ASA 3

2.02

(1.75 to 2.34)

< 0.001

ASA 4

2.95

(2.43 to 3.58)

< 0.001

Inpatient

1.22

(1.07 to 1.38)

0.002

Emergency case status

1.82

(1.58 to 2.11)

< 0.001

Female

0.92

(0.83 to 1.02)

0.115

Neuromuscular disease

1.39

(0.87 to 2.13)

0.145

After hours cases

1.21

(0.98 to 1.48)

0.071

End stage renal disease

1.36

(0.94 to 1.91)

0.094

Caucasian*

-

-

-

African American

1.64

(1.45 to 1.86)

< 0.001

Hispanic

0.93

(0.64 to 1.35)

0.71

Other

1.04

(0.76 to 1.4)

0.802

Case duration (30-min increments)

1.04

(1.02 to 1.05)

< 0.001

Abdominal/General surgery*

-

-

-

Burn surgery

0.86

(0.48 to 1.42)

0.578

Cardiac surgery

0.67

(0.28 to 1.37)

0.315

ENT surgery

0.67

(0.55 to 0.81)

< 0.001

Neurosurgery

0.63

(0.48 to 0.81)

0.001

Non-operating room anaesthesia

0.77

(0.57 to 1.01)

0.068

Orthopedic surgery

0.6

(0.51 to 0.69)

< 0.001

Plastic surgery

0.66

(0.52 to 0.82)

< 0.001

Thoracic surgery

1.4

(1.08 to 1.79)

0.009

Urogynecologic surgery

1.06

(0.9 to 1.25)

0.458

Vascular surgery

0.81

(0.6 to 1.06)

0.135

Other surgical procedures

0.9

(0.46 to 1.6)

0.746

Qualitative train of four 2, 3, or 4*

-

-

-

Qualitative train of four = 0 or 1

0.4

(0.36 to 0.45)

< 0.001

Rocuronium redosed

1.11

(0.96 to 1.28)

0.162

Rocuronium dose > 0.43 mg/kg/hr

2.29

(2.02 to 2.59)

< 0.001

Primary reversal with neostigmine < 48 min after last dose of rocuronium

1.43

(1.27 to 1.61)

< 0.001